Key result
Subantimicrobial doses of doxycycline did not significantly reduce the composite endpoint of sudden death, MI, or unstable angina compared with placebo (8.4% vs 0%, P=0.491).
Why the study?
Does subantimicrobial doses of doxycycline reduce the composite endpoint of sudden death, fatal MI, non-fatal MI, or troponin-positive unstable angina in patients with coronary artery disease?
Population
50 patients with coronary artery disease
Comparison
Subantimicrobial doses of doxycycline 20 mg… vs Placebo for 6 months
Design
RCT, Randomized (24 to placebo, 26 to SDD), Double-blind
Follow-up
6 months
Authors
Loading...
No support for subantimicrobial doxycycline in CAD event prevention; challenges biomarker surrogate validity in this pilot RCT.
RCT (n=50)
Double-blind
randomized
Does subantimicrobial doses of doxycycline reduce the composite endpoint of sudden death, fatal MI, non-fatal MI, or troponin-positive unstable angina in patients with coronary artery disease?
Absolute Event Rate: 8.4% vs 0%
p-value: p=0.491
In a pilot study of patients with coronary artery disease, subantimicrobial doses of doxycycline significantly reduced inflammatory biomarkers (CRP, IL-6, pro-MMP-9) but did not show a difference in clinical outcomes at 6 months.
Brown et al. (2004) conducted an RCT in coronary artery disease (n=50). Subantimicrobial doses of doxycycline (SDD) vs. Placebo was evaluated on Composite endpoint of sudden death, fatal myocardial infarction (MI), non-fatal MI, or troponin-positive unstable angina (p=0.491). Subantimicrobial doses of doxycycline did not significantly reduce the composite endpoint of sudden death, MI, or unstable angina compared with placebo (8.4% vs 0%, P=0.491).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: